Latest & greatest articles for trauma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on trauma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on trauma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for trauma

2. Prevalence and awareness of Anabolic Androgenic Steroids (AAS) among gymnasts in the western province of Riyadh, Saudi Arabia (PubMed)

Prevalence and awareness of Anabolic Androgenic Steroids (AAS) among gymnasts in the western province of Riyadh, Saudi Arabia Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir December 2017, Volume: 9, Issue: 12, Pages: 6050-6057, DOI: http://dx.doi.org/10.19082/6050 Corresponding author: Dr. Khaled Abdullah Al Bishi, Prince Sultan Military Medical City, Riyadh, Saudi Arabia. Tel: +966114326228, E-mail: dr-ksa1@hotmail.com Received: August 06, 2017, Accepted: October 22, 2017 (...) 6050 Prevalence and awareness of Anabolic Androgenic Steroids (AAS) among gymnasts in the western province of Riyadh, Saudi Arabia Khaled Abdullah Al Bishi 1 , Ayman Afify 2 1 M.B.B.S, Resident in Saudi Board of Family Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia 2 Consultant Family Medicine and EBM, MRCGP. Educ. Certify, Dundee University, United Kingdom Type of article: Original Abstract Background: Anabolic Androgenic Steroids (AAS) are synthetic derivatives of the male

Full Text available with Trip Pro

2017 Electronic physician

3. Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis (PubMed)

Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis 29164000 2018 11 13 2147-9720 4 3 2017 Sep European journal of rheumatology Eur J Rheumatol Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis. 184-188 10.5152/eurjrheum.2017.16113 Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by episodic and chronic inflammation that may lead to both accelerated coronary atherosclerosis (...) and cardiac AA amyloidosis. We hypothesized that late ventricular potentials (LPs), an established electrocardiographic susceptibility marker of ventricular arrhythmias, will be more common in FMF than in the adjusted normal population due to these two types of inflammation-associated cardiac effects. Therefore, we aimed to evaluate the occurrence of LPs in FMF patients with and without amyloidosis. Signal-averaged electrocardiography was performed in consecutive patients with FMF using the Frank

Full Text available with Trip Pro

2017 European journal of rheumatology

4. Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation

Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation WHO IRIS: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation Browse Related links Files in This Item: File Description Size Format 5.19 MB Adobe PDF 4.43 MB Adobe PDF Title: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation Authors: Issue Date: 2017 Publisher: World Health

2017 WHO

5. Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: summary

Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: summary WHO IRIS: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: summary Browse Related links Files in This Item: File Description Size Format 2.35 MB Adobe PDF Title: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: summary Authors: Issue Date: 2017 Publisher

2017 WHO

6. Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: brochure

Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: brochure WHO IRIS: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: brochure Browse Related links Files in This Item: File Description Size Format 517.86 kB Adobe PDF Title: Global accelerated action for the health of adolescents (AA-HA!): guidance to support country implementation: brochure Authors: Issue Date: 2017 Publisher

2017 WHO

7. Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP) (PubMed)

Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP) 27843608 2018 11 13 2059-7029 1 3 2016 ESMO open ESMO Open Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP). e000049 Fröbe Ana

Full Text available with Trip Pro

2016 ESMO open

8. Retraction: Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's syndrome. N Engl J Med 2008;359:1732. (PubMed)

Retraction: Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's syndrome. N Engl J Med 2008;359:1732. Retraction: Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's syndrome. N Engl J Med 2008;359:1732. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections (...) E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26630147 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 3;373(23):2280. doi: 10.1056/NEJMe1514259. Retraction: Ahimastos AA, Dart AM, Kingwell BA. Angiotensin II blockade in Marfan's syndrome. N Engl J Med 2008;359:1732. [No authors

2015 NEJM

9. Eprodisate disodium (Kiacta) for AA amyloidosis

Eprodisate disodium (Kiacta) for AA amyloidosis Eprodisate disodium (Kiacta) for AA amyloidosis Eprodisate disodium (Kiacta) for AA amyloidosis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Eprodisate disodium (Kiacta) for AA amyloidosis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 (...) Authors' objectives AA amyloidosis is a rare and serious condition that can happen as a complication of other chronic diseases such as rheumatoid arthritis. It leads to abnormal proteins being deposited throughout the body, but particularly affects the kidneys. Many patients eventually have kidney failure and need to start dialysis. At the moment, there is no treatment for AA amyloidosis itself, only the chronic disease that is causing it. Eprodisate disodium (Kiacta) is a new drug being developed

2015 Health Technology Assessment (HTA) Database.

10. Randomised controlled trial: A supplementation of DHA and AA to human milk-fed VLBW infants has no significant cognitive improvement or measurable neuroanatomical effects when evaluated at 8?years of age

Randomised controlled trial: A supplementation of DHA and AA to human milk-fed VLBW infants has no significant cognitive improvement or measurable neuroanatomical effects when evaluated at 8?years of age A supplementation of DHA and AA to human milk-fed VLBW infants has no significant cognitive improvement or measurable neuroanatomical effects when evaluated at 8 years of age | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A supplementation of DHA and AA to human milk-fed VLBW infants has no significant cognitive improvement or measurable

2015 Evidence-Based Medicine (Requires free registration)

11. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri (PubMed)

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri 23142059 2012 11 27 2013 02 04 2016 11 25 1474-5488 13 12 2012 Dec The Lancet. Oncology Lancet Oncol. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients (...) with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. 1210-7 10.1016/S1470-2045(12)70473-4 S1470-2045(12)70473-4 Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor signalling pathways implicated in the progression of the disease, including bone metastases. We assessed data for pain control and skeletal-related events prospectively

2012 EvidenceUpdates

12. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (PubMed)

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study 22995653 2012 10 02 2012 12 07 2015 11 19 1474-5488 13 10 2012 Oct The Lancet. Oncology Lancet Oncol. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. 983-92 (...) 10.1016/S1470-2045(12)70379-0 S1470-2045(12)70379-0 Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events). Between May 8, 2008, and July 28, 2009, this study enrolled 1195 patients at 147 sites in 13 countries

2012 EvidenceUpdates

13. Natural history and outcome in systemic AA amyloidosis. (PubMed)

Natural history and outcome in systemic AA amyloidosis. BACKGROUND: Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders. Little is known about the natural history of AA amyloidosis or its response to treatment. METHODS: We evaluated clinical features, organ function, and survival among 374 patients with AA amyloidosis who were followed for a median (...) regressed in 60% of patients who had a median SAA concentration of less than 10 mg per liter, and survival among these patients was superior to survival among those in whom amyloid deposits did not regress (P=0.04). CONCLUSIONS: The effects of renal dysfunction dominate the course of AA amyloidosis, which is associated with a relatively favorable outcome in patients with SAA concentrations that remain in the low-normal range (<4 mg per liter). Copyright 2007 Massachusetts Medical Society.

2007 NEJM

14. Eprodisate for the treatment of renal disease in AA amyloidosis. (PubMed)

Eprodisate for the treatment of renal disease in AA amyloidosis. 17554116 2007 06 07 2007 06 13 2016 11 22 1533-4406 356 23 2007 Jun 07 The New England journal of medicine N. Engl. J. Med. Eprodisate for the treatment of renal disease in AA amyloidosis. 2349-60 Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney (...) causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues. We performed a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of eprodisate in patients with AA amyloidosis and kidney involvement. We randomly assigned 183

2007 NEJM